[1] Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001 1;10(5):537-543.. [2] Balemans W, Van Hul W. Human genetics of SOST. J Musculoskelet Neuronal Interact.2006;6(4):355-356. [3] Brunkow M. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-589. [4] Delgado-Calle J, Sato A Y, Bellido T. Role and mechanism of action of sclerostin in bone. Bone.2016;96:29. [5] Wu Y, Xu SY, Liu SY, et al. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling. Eur Rev Med Pharmacol Sci. 2017;21(3):470-478. [6] Behets GJ, Viaene L, Meijers B, et al. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.Plos One.2017;12(5):e0176411. [7] Wei L, Guan L, Yan Z, et al. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol. 2016;48(12):2043-2050. [8] Shen J, Meyers CA, Shrestha S, et al. Sclerostin Expression in Skeletal Sarcomas. Human Pathology.2016;58:24-34. [9] Hudson BD, Hum NR, Thomas CB, et al. SOST Inhibits Prostate Cancer Invasion. Plos One.2015;10(11):e0142058. [10] Zhu M, Liu C, Li S, et al. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep. 2017;7(1):11399. [11] Ukita M, Yamaguchi T, Ohata N, et al. Sclerostin Enhances Adipocyte Differentiation in 3T3‐L1 Cells. J Cell Biochem. 2016;117(6): 1419-1428. [12] Koide M, Kobayashi Y, Yamashita T, et al. Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts. J Bone Miner Res. 2017;32(10):2074-2086. [13] Menezes ME, Devine DJ, Shevde L A, et al. Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer. 2012;130(7): 1477-1483. [14] Tian J, Xu XJ, Shen L, et al. Association of Serum Dkk-1 Levels with β-catenin in Patients with Postmenopausal Osteoporosis. J Huazhong Univ Sci Technolog Med Sci. 2015;35(2):212-218. [15] Xue J, Yang J, Yang L, et al. Dickkopf-1 Is a Biomarker for Systemic Lupus Erythematosus and Active Lupus Nephritis. J Immunol Res. 2017;2017:6861575. [16] Zarei A, Hulley PA, Sabokbar A, et al. Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips. Calcif Tissue Int.2017; 100(6):609-618. [17] Shen L, Wu X, Tan J, et al. Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer. Onco Targets Ther. 2017;10: 3545-3556. [18] Cui R, Lin Z, Li Z, et al. Assessment risk of osteoporosis in Chinese people: relationship among body mass index, serum lipid profiles, blood glucose, and bone mineral density. Clin Interv Aging. 2016;11: 887-895. [19] Pietrzyk B, Smertka M, Chudek J. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Advances in clinical and experimental medicine. Adv Clin Exp Med. 2017;26(8):1283-1291. [20] Xie W, Zhou L, Li S, et al. Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci. 2016;1364: 25-31. [21] Zimmerman Z F, Moon RT, Chien AJ. Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol. 2012;4(11). pii: a008086. [22] Zhou Y, Wang T, Hamilton JL, et al. Wnt/β-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis. Curr Rheumatol Rep. 2017 Sep;19(9):53. [23] Coulson J, Bagley L, Barnouin Y, et al. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults. Osteoporos Int. 2017;28(9):2683-2689. [24] Bhattoa HP, Wamwaki J, Kalina E, et al. Serum sclerostin levels in healthy men over 50Â years of age. J Bone Miner Metab. 2013;31(5): 579-584. [25] Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97(1):148-154. [26] Gerber LM, Bener A, Alali HM, et al. Bone Mineral Density in Midlife Women: the Study of Women’s Health in Qatar. Climacteric. 2015; 18(2):316-322.[27] Lloyd JT, Alley DE, Hawkes WG, et al. Body mass index is positively associated with bone mineral density in US older adults. Arch Osteoporos. 2014;9:175. [28] Metzger TA, Schwaner SA, Laneve AJ, et al. Pressure and shear stress in trabecular bone marrow during whole bone loading. J Biomech. 2015;48(12):3035-3043. [29] Yu O H Y, Richards B, Berger C, et al. The association between sclerostin and incident type 2 diabetes risk: a cohort study. Clin Endocrinol (Oxf). 2017;86(4):520-525. [30] Tsentidis C, Gourgiotis D, Kossiva L, et al. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density. Pediatric Diabetes. 2016;17(4):289-299. [31] Hygum K, Starup-Linde J, Harsløf T, et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(3): R137-R157. [32] Faienza M F, Ventura A, Delvecchio M, et al. High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2017;102(4): 1174-1181. [33] Sundararaghavan V, Mazur MM, Evans B, et al. Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2017;9(3):67-74. [34] Wongdee K, Charoenphandhu N. Up date on type 2 diabetes-related osteoporosis. World J Diabetes. 2015;6(5):673-678. [35] Cui LH, Shin MH, Chung EK, et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int. 2005;16(12):1975-1981. [36] Li S, Guo H, Liu Y, et al. Relationships of serum lipid profiles and bone mineral density in postmenopausal Chinese women. Clin Endocrinol (Oxf). 2015;82(1):53-58. [37] Cosman F, Crittenden D B, Adachi J D, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-1543. [38] Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216-24. [39] Butler JS, Murray DW, Hurson CJ, et al. The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density. J Orthop Res. 2011;29(3):414-418. [40] Dovjak P, Dorfer S, Kudlacek S, et al. Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status.Gerontology. 2014;60(6):493-501. [41] Hampson G, Edwards S, Conroy S, et al. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.Bone.2013;56(1):42-47. [42] Glantschnig H, Hampton R A, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285(51):40135-40147. [43] Goldstein S D, Matteo T, Bautista G W, et al. A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget, 2016;7(16):21114-21123. [44] Kato T, Khanh VC, Sato K, et al. Elevated expression of Dkk-1 by glucocorticoid treatment impairs bone regenerative capacity of adipose tissue-derived mesenchymal stem cells. Stem Cells Dev. 2018;27(2):85-99. [45] Monica F, Kannan G, Marina S, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505. |